Table 1.
General characteristics of B-cell lymphoma cases and controls.
| Matched pairs, n = 1,032 | All subjects, n = 1,042b | |||||
|---|---|---|---|---|---|---|
| Cases, n = 516 | Controls, n = 516 | p | Cases, n = 517 | Controls, n = 525 | p | |
| Agea | 55.2 (9.11) | 55.2 (9.11) | 0.99 | 55.2 (9.09) | 55.2 (9.08) | 0.92 |
| Female, n (%) | 301 (58.3) | 301 (58.3) | 1.00 | 301 (58.2) | 305 (58.1) | 1.00 |
| Height, cma | 166.3 (9.09) | 165.8 (9.39) | 0.35 | 166.3 (9.09) | 165.8 (9.38) | 0.37 |
| BMI, kg/m2a | 26.6 (4.40) | 26.3 (3.92) | 0.26 | 26.6 (4.39) | 26.3 (3.91) | 0.26 |
| Education, n (%) | 0.40 | 0.41 | ||||
| None | 41 (7.9) | 37 (7.2) | 41 (7.9) | 38 (7.2) | ||
| Primary school | 175 (33.9) | 159 (30.8) | 176 (34) | 162 (30.9) | ||
| Technical/professional school | 131 (25.4) | 121 (23.4) | 131 (25.3) | 123 (23.4) | ||
| Secondary school | 74 (14.3) | 92 (17.8) | 74 (14.3) | 92 (17.5) | ||
| University/college | 95 (18.4) | 107 (20.7) | 95 (18.4) | 110 (21) | ||
| Smoking status, n (%) | 0.98 | 0.98 | ||||
| Never smoker | 238 (46.1) | 241 (46.7) | 238 (46) | 244 (46.5) | ||
| Former smoker | 168 (32.6) | 167 (32.4) | 169 (32.7) | 169 (32.2) | ||
| Current smoker | 110 (21.3) | 108 (20.9) | 110 (21.3) | 112 (21.3) | ||
| Alcohol intake, gr/dayc | 5.5 (0–124.2) | 4.7 (0–235.2) | 0.56 | 5.5 (0–124.2) | 4.7 (0–235.2) | 0.67 |
| Physical activity, n (%) | 0.93 | 0.96 | ||||
| Inactive | 136 (26.4) | 135 (26.2) | 137 (26.5) | 137 (26.1) | ||
| Moderately inactive | 159 (30.8) | 166 (32.2) | 159 (30.8) | 168 (32) | ||
| Moderately active | 110 (21.3) | 112 (21.7) | 110 (21.3) | 113 (21.5) | ||
| Active | 111 (21.5) | 103 (20) | 111 (21.5) | 107 (20.4) | ||
| Country, n (%) | 1.00 | 1.00 | ||||
| Italy | 100 (19.4) | 100 (19.4) | 100 (19.3) | 104 (19.8) | ||
| Spain | 95 (18.4) | 95 (18.4) | 95 (18.4) | 96 (18.3) | ||
| UK | 143 (27.7) | 143 (27.7) | 144 (27.9) | 143 (27.2) | ||
| Netherlands | 96 (18.6) | 96 (18.6) | 96 (18.6) | 97 (18.5) | ||
| Greece | 22 (4.3) | 22 (4.3) | 22 (4.3) | 22 (4.2) | ||
| Germany | 60 (11.6) | 60 (11.6) | 60 (11.6) | 63 (12) | ||
| sCD23, pg/mLa | 8.15 (0.66) | 7.71 (0.39) | < 0.0001 | 8.15 (0.66) | 7.71 (0.38) | < 0.0001 |
| sCD30, ng/mla | 2.85 (0.54) | 2.67 (0.35) | < 0.0001 | 2.85 (0.54) | 2.67 (0.35) | < 0.0001 |
| sCD27, U/mla | 3.59 (0.39) | 3.46 (0.30) | < 0.0001 | 3.60 (0.40) | 3.46 (0.31) | < 0.0001 |
| CXCL13, pg/mLa | 3.38 (0.81) | 3.08 (0.59) | < 0.0001 | 3.37 (0.81) | 3.09 (0.59) | < 0.0001 |
| Lymphoma subtypes, n (%) | ||||||
| DLBCL | 174 (33.7) | – | 174 (33.7) | – | ||
| CLL | 210 (40.7) | – | 211 (40.8) | – | ||
| FL | 132 (25.6) | – | 132 (25.5) | – | ||
aMean (SD); Body mass index (BMI); diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL).
bone CLL and 9 controls lacked paired samples ; Due to limited sample volume, sCD27 and CXCL13 were not measured in 5 and 11 samples, respectively. So sample size for those markers are as: Matched analyses: CD27 (511 pairs), CXCL13 (506 pairs). Unmatched analyses: CD27 (515 cases/522 controls), CXCL13 (511/520).
cMedian (min–max). Bold: statistically significant at p-value ≤ 0.05.